Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Prices IPO at $39 Per Share

NEW YORK – 10x Genomics today priced its initial public offering of 10 million shares of its common stock at $39 per share.

The Pleasanton, California-based single-cell sequencing firm said that underwriters will have the right to purchase up to an additional 1.5 million shares of its common stock at the IPO price.

In a filing with the US Securities and Exchange Commission, 10x said that net proceeds from the offering will be approximately $357.5 million, or approximately $411.9 million if the underwriters exercise their option to purchase additional shares in full.

The shares are expected to begin trading today on the Nasdaq Global Select Market under the symbol "TXG" and the offering is expected to close on Sept. 16, 2019, subject to customary closing conditions.

JP Morgan Securities, Goldman Sachs, and Bank of America Merrill Lynch are acting as lead joint book-running managers for the offering. Cowen is acting as lead manager for the offering. In a preliminary prospectus filed in August, 10x initially said that it was looking to raise up to $100 million in its IPO. Earlier this month, the company upped its offering, noting that it planned to sell up to 9 million shares of stock at a price of $31 to $35 per share, for expected net proceeds of around $271 million.

The company has maintained that it intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. It also said that it may use a portion of the net proceeds to acquire businesses, products, or technologies, though noted that it does not currently have agreements or commitments for any material acquisitions.

10x is embroiled in intellectual property lawsuits on multiple fronts, including with Bio-Rad, which filed a new suit against 10x yesterday.

10x is also party to a loan and security agreement with Silicon Valley Bank, under which $30.0 million of term loan borrowings were outstanding. The firm also had a $25.0 million revolving line of credit and up to $20.0 million of additional term loan borrowings available to be drawn before Dec. 31, 2019, but this week amended the terms of the loan such that SVB would provide it with a $45.0 million revolving line of credit, or $65.0 million if 10x raises gross cash proceeds of at least $100 million in its IPO.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.